Compare IDIX to:
Real-Time: 2.11 0.01 (0.48%) 2:22pm ET
| Last Trade: | 2.12 |
|---|---|
| Trade Time: | 2:06pm ET |
| Change: | |
| Prev Close: | 2.10 |
| Open: | 2.11 |
| Bid: | 2.11 x 3400 |
| Ask: | 2.12 x 2400 |
| 1y Target Est: | 4.60 |
| Day's Range: | 2.10 - 2.16 |
|---|---|
| 52wk Range: | 1.81 - 6.78 |
| Volume: | 29,689 |
| Avg Vol (3m): | 166,585 |
| Market Cap: | N/A |
| P/E (ttm): | N/A |
| EPS (ttm): | N/A |
| Div & Yield: | N/A (N/A) |
| Wed, Nov 4 | IDENIX PHARMACEUTICALS INC FinancialsEDGAR Online Financials |
| Tue, Nov 3 | Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)PR Newswire |
| Fri, Oct 30 | Movers roundup: Novatel Wireless, HarmanAP |
| Fri, Oct 30 | Idenix down; Novartis won't license drug candidateAP |
| Fri, Oct 30 | Idenix Pharma downgraded by Caris & CompanyBriefing.com |
| Fri, Oct 30 | YRC Worldwide, AXT: Early Volume Playsat TheStreet.com |
| Fri, Oct 30 | Idenix 3Q loss narrows as costs fall, revenue upAP |
| Fri, Oct 30 | Novartis not licensing Idenix's hepatitis C drugAP |
| Fri, Oct 30 | Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)PR Newswire |
| Thu, Oct 29 | Idenix Pharmaceuticals, Inc. Earnings Call scheduled for 4:30 pm ET todayCCBN |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.